EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Wednesday, July 10th 2019 at 8:05pm UTC BEIJING–(BUSINESS WIRE)– Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quarter ended March 31, 2019. First Quarter of 2019 Financial Summary Sales for the first …
Plus »AG Mednet and Median Technologies Partnership Supports Global Clinical Trials Portfolio, Including Extensive Programs in China
Monday, July 8th 2019 at 3:45pm UTC BOSTON & SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)– Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® (ALMDT:PA) and AG Mednet have renewed their partnership to use AG Mednet’s global infrastructure for the collection, QC and delivery of medical images and ancillary data in support …
Plus »Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Tuesday, July 2nd 2019 at 11:30am UTC WILMINGTON, Del. & SHANGHAI–(BUSINESS WIRE)– Incyte (NASDAQ:INCY) and Zai Lab Ltd. (NASDAQ:ZLAB) today announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. This press release …
Plus »Terns Pharmaceuticals Appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer
Monday, July 1st 2019 at 9:00am UTC FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)– Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, announced today the appointment of Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer. This press …
Plus »Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region
Monday, June 24th 2019 at 8:31pm UTC -GENFIT partnership expands Terns’ portfolio, adding a Phase 3 product with a complementary mechanism of action well-suited to combinations with Terns’ NASH assets- FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)– Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), …
Plus »EXUMA Biotechnology Expands Leadership Team with Appointment of Chief Medical Officer and Chief Financial Officer
Tuesday, June 18th 2019 at 10:00pm UTC Wendy Li, M.D. to Serve as Chief Medical Officer Based in Shanghai James Samuels Named Chief Financial Officer to Be Based in Hong Kong and West Palm Beach SHANGHAI & WEST PALM BEACH, Fla.–(BUSINESS WIRE)– EXUMA Biotechnology, a clinical-stage biotechnology company discovering and …
Plus »Harbour BioMed Appoints Immunology Research Leader Kenneth M. Murphy, MD, PhD, to Its Scientific Advisory Board
Wednesday, June 19th 2019 at 12:00am UTC CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI–(BUSINESS WIRE)– Harbour BioMed (“HBM”) announced today the appointment of Kenneth M. Murphy, MD, PhD, to the company’s scientific advisory board. Dr. Murphy, a member of the National Academy of Sciences and a Howard Hughes Medical …
Plus »Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions
Monday, June 17th 2019 at 12:00pm UTC VT-1161 is a potent antifungal therapy with the potential to treat a range of fungal infections, including those resistant to currently approved treatment options The agreement grants to Hengrui the exclusive rights to develop and commercialize VT-1161 in China and grants to Mycovia …
Plus »Parexel Teams with CLARINESS to Enhance Patient Access and Engagement in China
Wednesday, June 12th 2019 at 1:00pm UTC Collaboration expands Parexel’s capabilities in the region for patient access through China’s native social media channels; enhances ongoing engagement through CLARINESS’s digital patient recruitment portal BOSTON–(BUSINESS WIRE)– Parexel, a leader in the development of innovative new therapies to improve the world’s health, today …
Plus »Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
Wednesday, June 12th 2019 at 10:00am UTC ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)– Harbour BioMed (HBM) and Erasmus MC, University Medical Center Rotterdam announced today that they have signed a 10-year Memorandum of Understanding (MOU) to enable a broad range of joint basic, translational and clinical research …
Plus »
